Who are Adalimumab biosimilar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TDM-based infliximab intravenous therapy, etanercept or adalimumab, Adalimumab with methotrexate, PRECISION dosing Infliximab, Infliximab Adalimumab y Golimumab, CYCLOSPORINE VS INFLIXIMAB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adalimumab-biosimilar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Adalimumab biosimilar — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adalimumab biosimilar (Adalimumab biosimilar) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

phase 3 TNF-alpha inhibitor TNF-alpha (Tumor Necrosis Factor-alpha) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Adalimumab biosimilar (Adalimumab biosimilar) — Alvotech Swiss AG. Adalimumab biosimilar is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adalimumab biosimilar TARGET	Adalimumab biosimilar	Alvotech Swiss AG	phase 3	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
TDM-based infliximab intravenous therapy	TDM-based infliximab intravenous therapy	Asan Medical Center	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
etanercept or adalimumab	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Adalimumab with methotrexate	Adalimumab with methotrexate	Pfizer	marketed	TNF-alpha inhibitor + DMARD combination	TNF-alpha; dihydrofolate reductase
PRECISION dosing Infliximab	PRECISION dosing Infliximab	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	TNF-alpha inhibitor monoclonal antibody	TNF-alpha (Tumor Necrosis Factor-alpha)
Infliximab Adalimumab y Golimumab	Infliximab Adalimumab y Golimumab	Fundación de Investigación Biomédica - Hospital Universitario de La Princesa	marketed	TNF-alpha inhibitor	TNF-alpha (Tumor Necrosis Factor-alpha)
CYCLOSPORINE VS INFLIXIMAB	CYCLOSPORINE VS INFLIXIMAB	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	Immunosuppressant (cyclosporine); TNF-alpha inhibitor (infliximab)	Calcineurin (cyclosporine); TNF-alpha (infliximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

Abbott · 4 drugs in this class
Centre for Human Drug Research, Netherlands · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 2 drugs in this class
Alvotech Swiss AG · 2 drugs in this class
UCB Pharma · 2 drugs in this class
Celltrion · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
Asan Medical Center · 1 drug in this class
Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adalimumab biosimilar — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-biosimilar. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing